Durvalumab: Previous Findings and Current Research

Share this content:
Several ongoing clinical trials are also evaluating durvalumab as a single agent or in combination with other therapies, such as tremelimumab, and as a first-line therapy.
Several ongoing clinical trials are also evaluating durvalumab as a single agent or in combination with other therapies, such as tremelimumab, and as a first-line therapy.

Lung cancer is one of a handful of solid tumors that have seen outcomes improve with the use of immune checkpoint inhibitors. Nivolumab and pembrolizumab, PD-1 inhibitors, and the PD-L1 inhibitor, atezolizumab, are already approved by the US Food and Drug Administration (FDA) for patients with previously treated advanced non–small cell lung cancer (NSCLC). Durvalumab, another PD-L1 inhibitor, may be next.

Like atezolizumab, durvalumab targets PD-L1, blocking any PD-L1 interaction with PD-1 and CD80 on T cells and consequently inducing an immune response. In July, the FDA granted durvalumab breakthrough therapy designation for patients with locally advanced unresectable NSCLC whose disease had not progressed after platinum-based chemoradiation.1

The designation was based on interim results from the phase 3 PACIFIC trial (ClinicalTrials.gov Identifier: NCT02125461), which evaluated durvalumab as a sequential treatment among these patients. The trial randomly assigned 713 patients 2:1 to durvalumab 10 mg/kg or placebo every 2 weeks for up to 12 months.

In October, the FDA granted durvalumab priority review after the full results of PACIFIC were presented at the European Society for Medical Oncology (ESMO) 2017 Congress in Madrid and published in The New England Journal of Medicine.2 The updated results showed that durvalumab significantly prolonged progression-free survival (PFS) compared with placebo.

The median PFS for durvalumab was triple that of placebo, at 16.8 months compared with 5.6 months, respectively (hazard ratio [HR], 0.52; 95% CI, 0.42-0.65; P < .001). The 12-month PFS rate was 44.2% compared with 27.0% for placebo.

Page 1 of 2

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters